A mere 20 years after it was first developed at the Hershey Medical Center in Pennsylvania with funding from Vertex, Baloxavir marboxil a one-dose influenza (flu) integrase-inhibitor will be approved in various countries around the world and released by Roche and Shionogi Pharmaceuticals.
If you want Baloxavir marboxil right away a year or two early, gram quantities are costly but available "for research purposes only, wink-wink, say no more".
Baloxavir is mixed with DMSO, a paper pulp byproduct which allows large molecules to pentrate skin and other tissue, as a method of administration.
Roche also sells the much less effective Tamiflu which acts on a variable flu gene and Johnson & Johnson whose unapproved pimodovir works in a similar manner on a different but also variable influenza structure.
Nizoral, an anti-parasitic already on market which can be prescribed by any physician off-label, reduces the number of new influenza virus released by infected cell, also by acting on a viral structure, and is in clinical trials, but has nowhere near the effectiveness of Baloxavir.
Market Data 
Markets 
AI
